Although the majority of metastatic CRC patients had HER2 (ERBB2) amplification33, our study only considered mutations, not amplifications, and moreover HER2 amplification in one of our patients might be insufficient to explain biology in ovarian metastasis. Here, ERBB2 is linked to colorectal carcinoma.